William Makis (makisw.substack.com), 2026-04-07: Makis post publicly reporting the Hulscher et al. survey of 197 patients (84.4% clinical benefit, 32.8% no evidence of disease, 15.6% tumour regression) and describing his own programme's 75-80% reported clinical benefit.
@NicHulscher and colleagues conducted a survey of 197 Cancer patients taking Ivermectin and Mebendazole for 6 months and confirmed:
William Makis (makisw.substack.com), 2026-04-07: Makis post publicly reporting the Hulscher et al. survey of 197 patients (84.4% clinical benefit, 32.8% no evidence of disease, 15.6% tumour regression) and describing his own programme's 75-80% reported clinical benefit. C4. Study type: author's commentary on someone else's unpublished-at-the-time dataset; no new patients of his own are enumerated in the free portion. The post says 'This confirms what we've seen in the 9000+ Cancer patients we helped in our largest Ivermectin Cancer Project in the world!!' and 'I've often talked about a 75-80% clinical benefit that patients reported when they came to us'. PATIENT-REPORTED, NOT INDEPENDENTLY VERIFIED. IMPORTANT STATUS NOTE: the underlying paper (Hulscher et al., Anticancer Research 2026;46(6):3243-3255) was RETRACTED in October 2026, after this post; Makis's post therefore reports figures the journal has since withdrawn. The post is behind a partial paywall – only the opening portion was read.
